Rani Therapeutics Holdings, Inc., a clinical-stage bio-therapeutics company based in San Jose, California, focuses on developing the RaniPill capsule for oral delivery of biologics, replacing injections. The company, which went public in 2021, employs 163 people and has products like RT-101 for treating NETs and acromegaly in its pipeline.
Rani Therapeutics Holdings (RANI) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Rani Therapeutics Holdings's actual EPS was -$0.26, beating the estimate of -$0.32 per share, resulting in a 19.25% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
